Tom McAndrew, a computational scientist and associate professor in Lehigh's College of Health, recently published a paper in ...

The risk for medically attended influenza illness was lower among patients who received the influenza vaccine in the 2023 to 2024 season, with variations in protection observed across age groups ...

The 2024-2025 COVID-19 and influenza vaccines provided protection against ED/UC, outpatient visits, and hospitalizations. In the 2024-2025 season, the COVID-19 vaccine provided additional ...

"A planned March 13 meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee on the influenza vaccine strains for the 2025-2026 influenza season in the northern ...

Recombinant quadrivalent influenza vaccine (RIV4) and standard egg-based quadrivalent inactivated IV (IIV4) show comparable effectiveness in reducing influenza-related hospitalization among older ...

The global influenza vaccines market is projected to reach US$ 12.16 Billion by 2032, from US$ 7.60 Billion in 2024. According to data published by the World Health Organization (WHO) in 2023 ...

Both candidates combine 2 already licensed vaccines to prevent influenza and COVID-19. Fast Track designation was granted with the aim of addressing the significant individual and health system ...

13 Sampling weights were created to adjust ... using directed acyclic graph analysis (appendix p 12). Confounders identified were the individual's age (categorised as mentioned previously), receipt of ...

obstetricians should determine the optimal timing for administration of influenza vaccine for each individual pregnancy considering the benefits to the pregnant person, the fetus, and the infant ...

New York, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The global influenza vaccine market, valued at US$ 8.2 billion in 2022, is projected to experience substantial growth, reaching an estimated US$ 18.5 ...